My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Novo Nordisk A/S Common Stock (NY:NVO)

40.81 UNCHANGED

Streaming Delayed Price Updated: 7:00 PM EDT, Apr 15, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Why Viking Therapeutics Stock Is Up More Than 9% Today ↗

February 23, 2026

A potential competitive threat to Viking's phase 3 weight-loss drug VK2735 was just dealt a major blow.

Via The Motley Fool

Novo Nordisk A/S Investigated on Behalf of Investors - Contact the DJS Law Group to Discuss Your Rights – NVO

February 23, 2026

From The DJS Law Group

Via Business Wire

Why Eli Lilly Stock Just Popped ↗

February 23, 2026

Eli Lilly has some good news for investors today. Novo Nordisk has some bad news (which is also good news for Lilly).

Via The Motley Fool

Why Novo Nordisk Stock Just Crashed ↗

February 23, 2026

GLP-1 weight loss drug CagriSema may not be the salvation Novo Nordisk was hoping for.

Via The Motley Fool

High Volatility and Earnings Crossroads: A Deep Dive into Hims & Hers Health (HIMS) in 2026

February 23, 2026

As of February 23, 2026, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself at a critical crossroads that has sent shockwaves through the telehealth and pharmaceutical sectors. Once the darling of the...

Via Finterra

NVO Investors Have Opportunity to Join Novo Nordisk A/S Fraud Investigation with the Schall Law Firm

February 23, 2026

From The Schall Law Firm

Via Business Wire

Eli Lilly Surges as Novo Nordisk’s "CagriSema" Stumbles in High-Stakes Obesity Head-to-Head

February 23, 2026

Shares of Eli Lilly (NYSE: LLY) climbed 3.5% on February 23, 2026, as the pharmaceutical giant tightened its grip on the multi-billion-dollar obesity market. The rally was fueled by disappointing...

Via MarketMinute

Novo Nordisk Shares Plunge 13% as Next-Gen Weight Loss Drug CagriSema Fails to Topple Eli Lilly in Landmark Trial

February 23, 2026

COPENHAGEN — Shares of the Danish pharmaceutical giant Novo Nordisk (NYSE: NVO) plummeted more than 13% in premarket trading on Monday, February 23, 2026, following the release of highly anticipated...

Via MarketMinute

Topics Earnings

These stocks are moving in today's pre-market session ↗

February 23, 2026

Via Chartmill

1 Reason I'm Seriously Considering Novo Nordisk as a Buy‑and‑Never‑Sell Obesity Stock ↗

February 23, 2026

Novo Nordisk investors get a second bite at the Ozempic apple.

Via The Motley Fool

3 Reasons Viking Therapeutics Stock Could 10X if Its Obesity Pipeline Succeeds ↗

February 23, 2026

Viking stock has plenty of room to run.

Via The Motley Fool

Why Is NVO Stock Falling Pre-Market Today? ↗

February 23, 2026

The company stated that CagriSema demonstrated 23% weight loss in people with obesity, failing to meet its primary endpoint.

Via Stocktwits

Topics Government

2 Unstoppable Dividend Stocks to Buy Right Now for Less Than $200 ↗

February 22, 2026

These two healthcare stocks are likely headed higher from their current prices.

Via The Motley Fool

Hims & Hers in Free Fall: Why Analysts See Nearly 150% Upside ↗

February 21, 2026

Via MarketBeat

Novo Nordisk Stock Investors Just Got Great News From Eli Lilly ↗

February 20, 2026

But it's good news for Eli Lilly, too.

Via The Motley Fool

Is Pfizer Stock the Only Big Pharma Name I'd Buy and Hold Through Any Market Crash? ↗

February 20, 2026

New products are already generating growth.

Via The Motley Fool

Topics Intellectual Property

2 Innovative Biotech Stocks That May Climb 58% and 200%, According to Wall Street ↗

February 19, 2026

These biotech companies have catalysts ahead.

Via The Motley Fool

Warning: This Skyrocketing Stock Has a Hidden Risk ↗

February 19, 2026

Eli Lilly is leading the pack in the GLP-1 weight-loss drug market, but this good news won't last forever.

Via The Motley Fool

Topics Intellectual Property

Overlooked and Undervalued: Why Novo Nordisk Stock Deserves Attention ↗

February 19, 2026

Novo Nordisk looks attractively priced even though 2026 is likely to be a tough year.

Via The Motley Fool

Hims & Hers HUGE Acquisition News! ↗

February 19, 2026

Hims & Hers is acquiring Eucalyptus and spreading its wings internationally.

Via The Motley Fool

Forget Ozempic: This Obesity‑Drug Giant Is Grabbing the Biggest Slice of the GLP‑1 Gold Rush ↗

February 19, 2026

Ozempic's rival is generating blockbuster revenue and gaining market share.

Via The Motley Fool

The Trillion-Dollar Pharmaceutical Giant: Eli Lilly Makes History as Weight-Loss Revolution Drives Unprecedented Growth

February 17, 2026

In a historic moment for the global healthcare industry, Eli Lilly and Company (NYSE:LLY) has officially cemented its position as the world’s first pharmaceutical company to surpass a $1 trillion...

Via MarketMinute

Topics Earnings Economy

NVO Stock Generates Retail Buzz After European Commission Approves 7.2 MG Once-Weekly Dose Of Wegovy Injection ↗

February 17, 2026

The approval follows a positive recommendation from the European Medicines Agency and is supported by data from clinical trials involving more than 1,400 participants.

Via Stocktwits

Topics Lawsuit

2026 Could Be a Big Year for Viking Therapeutics. Time to Buy? ↗

February 17, 2026

Viking should have plenty of news to share with investors this year.

Via The Motley Fool

Novo Nordisk's New Diabetes Drug Outshines Ozempic: Is The Stock a Buy? ↗

February 16, 2026

Novo Nordisk's plan to gain ground in the GLP-1 space is slowly taking shape.

Via The Motley Fool

Got $500? 2 Pharma Stocks to Buy and Hold Forever. ↗

February 14, 2026

Growth, value, or both?

Via The Motley Fool

Novo Nordisk To Meet Wegovy Pill Demand In US Before Expanding To Avoid Supply Shortage, Says CEO Doustdar ↗

February 13, 2026

Novo is looking to ensure the U.S. market is supplied before choosing another country to scale in, Doustdar said in an interview with CNBC.

Via Stocktwits

Topics Lawsuit

Meet the 6.3% Yield Dividend Stock That Could Soar in 2026 ↗

February 13, 2026

Pfizer's long-acting GLP-1 weight loss candidate could set the stage for a stock rally.

Via The Motley Fool

Topics Intellectual Property

VKTX Stock Has Nearly 300% Wall Street Upside — Is Viking’s Oral Obesity Pill The Next Novo Nordisk-Style Breakout? ↗

February 12, 2026

The company ended 2025 with $706 million in cash, which it said is enough to fund ongoing Phase 3 trials and maintenance data readouts.

Via Stocktwits

Eli Lilly vs Novo Nordisk in the Weight Loss Drug Market: Here's What Investors Need to Know. ↗

February 12, 2026

Both companies are betting on interest in weight loss pills.

Via The Motley Fool

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.